GLENHAWK

Glenmark is a global pharmaceutical company headquartered in Mumbai, India, with a significant presence in generics, specialty medicines, and innovative drug discovery. The company focuses on therapeutic areas such as oncology, dermatology, and respiratory diseases, maintaining a robust pipeline of both small molecules and biologics. A key highlight of their innovation strategy is the proprietary BEAT platform, which facilitates the development of next-generation bispecific antibodies. Glenmark operates multiple R&D centers and manufacturing facilities globally, serving markets in over 80 countries. Their commercial portfolio includes a wide range of branded and generic products, including the first-to-launch Ryaltris for allergic rhinitis.